They’re relatively small now, but these biotechs could be monster-sized winners over the long run.
Think of any big biotech. What comes to mind? Perhaps you thought of the blockbuster drugs the company already has on the market. Maybe you considered its pipeline candidates or its solid cash flow.
Now think about the same biotech 10 or 20 years ago. For most of the biggest companies, the picture a decade or two ago looked much different than it does today — even the biggest biotechs were once much smaller.
Which companies that are relatively small right now could become the big biotechs of the future? Here’s why I think that Editas Medicine (NASDAQ:EDIT), Ligand Pharmaceuticals(NASDAQ:LGND), and Exelixis (NASDAQ:EXEL) could be monster biotech stocks in the making…
Continue reading at THE MOTLEY FOOL